Search results
1 lip 2019 · The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
Individualized Lung Cancer Risks and Screening Benefit Calculator. DCEG investigators developed models to estimate a current or former smoker’s risk of developing lung cancer and their gain in life-expectancy from lung cancer screening, freely available online at ScreenLC.com. These models included:
14 gru 2017 · ASP8273 demonstrated antitumor activity in patients with EGFR-mutant lung cancers after prior treatment with EGFR TKIs. This study identified the ASP8273 RP2D to be 300 mg daily based on pharmacokinetics, pharmacodynamics, safety, and antitumor activity; the MTD was not established.
7 sty 2022 · A blood-based biomarker panel in combination with PLCO m2012 significantly improves lung cancer risk assessment for lung cancer screening.
4 sie 2023 · Risk stratification and individualized risk assessment could improve the performance of lung cancer screening by identifying high-risk individuals who may benefit from screening.
20 maj 2015 · ASP8273 was administered once daily at doses of 25 mg to 400 mg. Endpoints included safety and tolerability, PK and preliminary anti-tumor activity. Response expansion cohorts enrolled subjects with known EGFR T790M mutation and required submission of tissue samples for central confirmatory testing.
15 gru 2017 · ASP8273 is a third-generation EGFR TKI with antitumor activity in preclinical models of EGFR-mutant lung cancer that targets mutant EGFR, including EGFR T790M.
